SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech lists with 4.57% discount on the BSE

16 Aug 2021 Evaluate

Windlas Biotech has debuted at Rs 439.00 on the BSE, down by 21 points or 4.57% from its issue price of Rs 460.

The scrip is currently trading at Rs 416.55, down by 43.45 points or 9.45% from its issue price. It has touched a high and low of Rs 452.10 and Rs 407.25 respectively. So far 2.33 lakh shares were traded on the counter.

The offering, which was open for subscription between August 04, 2021 and August 06, 2021, was subscribed 22.46 times. The issue price was fixed at Rs 460 per share i.e. at upper end of price band of Rs 448-460 apiece.

Windlas Biotech is into domestic pharmaceutical formulations contract development and manufacturing business.

Windlas Biotech Share Price

865.40 -6.35 (-0.73%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×